导管变异型前列腺癌与显著缩短的无转移生存相关
这项国际多中心研究比较了202例导管腺癌与2037例腺泡腺癌前列腺切除患者,倾向评分匹配后导管变异型患者的挽救治疗无失败生存(8.1 vs 22.0个月,p=0.03)和无转移生存(6.7 vs 78.6个月,p<0.0001)均显著更短。导管变异型一致与RB1缺失及TAP1、SLC4A2、EHHADH拷贝数增加相关。
要点
- 前列腺切除标本中任何导管变异型成分均提示更差临床结局
- 导管变异型患者无转移生存显著短于纯腺泡腺癌(6.7 vs 78.6个月)
- 导管变异型与RB1缺失及特定基因拷贝数增加相关
核心结论
- 前列腺切除时存在任何导管变异型腺癌预示比纯腺泡癌更差的临床结局,表现为挽救治疗启动时间和转移性疾病发生时间显著缩短。
研究设计与样本
- 国际多中心研究,从两个机构数据库识别接受根治性前列腺切除术的导管变异型组织学患者,并与独立腺泡腺癌队列比较。
- 共分析202例导管腺癌和2037例腺泡腺癌病例,倾向评分匹配后评估生化复发、挽救治疗启动和转移性疾病发生时间。
- 对选定的8例病例进行深度全外显子组测序。
主要发现
- 匹配后生存分析显示导管变异型组织学患者挽救治疗无失败生存更短(8.1 vs 22.0个月,p=0.03)。
- 导管变异型组织学患者无转移生存更短(6.7 vs 78.6个月,p<0.0001)。
- 导管变异型组织学一致与RB1缺失以及TAP1、SLC4A2和EHHADH拷贝数增加相关。
关键数值与推荐
- 导管变异型 vs 腺泡腺癌:挽救治疗无失败生存8.1 vs 22.0个月,p=0.03。
- 导管变异型 vs 腺泡腺癌:无转移生存6.7 vs 78.6个月,p<0.0001。
临床怎么用
- 前列腺切除标本中检测到导管变异型成分时,应视为高危特征,需更密切监测转移和考虑早期挽救治疗干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ductal adenocarcinoma is an uncommon prostate cancer variant. Previous studies suggest that ductal variant histology may be associated with worse clinical outcomes, but these are difficult to interpret. To address this, we performed an international, multi-institutional study to describe the characteristics of ductal adenocarcinoma, particularly focussing on the effect of presence of ductal variant cancer on metastasis-free survival. METHODS: Patients with ductal variant histology from two institutional databases who underwent radical prostatectomies were identified and compared with an independent acinar adenocarcinoma cohort. After propensity score matching, the effect of the presence of ductal adenocarcinoma on time to biochemical recurrence, initiation of salvage therapy and the development of metastatic disease was determined. Deep whole-exome sequencing was performed for selected cases (n = 8). RESULTS: A total of 202 ductal adenocarcinoma and 2037 acinar adenocarcinoma cases were analysed. Survival analysis after matching demonstrated that patients with ductal variant histology had shorter salvage-free survival (8.1 versus 22.0 months, p = 0.03) and metastasis-free survival (6.7 versus 78.6 months, p < 0.0001). Ductal variant histology was consistently associated with RB1 loss, as well as copy number gains in TAP1, SLC4A2 and EHHADH. CONCLUSIONS: The presence of any ductal variant adenocarcinoma at the time of prostatectomy portends a worse clinical outcome than pure acinar cancers, with significantly shorter times to initiation of salvage therapies and the onset of metastatic disease. These features appear to be driven by uncoupling of chromosomal duplication from cell division, resulting in widespread copy number aberration with specific gain of genes implicated in treatment resistance.
引用
- Chow K, Bedő J, Ryan A, et al. Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. Eur J Cancer. 2021. PMID: 33678516. doi:10.1016/j.ejca.2020.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。